Skip to main content
Top
Published in: Clinical and Translational Oncology 5/2014

01-05-2014 | Research Article

Overexpression of nuclear β-catenin at invasive front in rectal carcinoma is associated with lymph node metastasis and poor prognosis

Authors: L. Wang, X. Zhang, Z. Li, J. Chai, G. Zhang, Z. Yu, Y. Cheng, S. Hu

Published in: Clinical and Translational Oncology | Issue 5/2014

Login to get access

Abstract

Background

This study aims to investigate whether nuclear β-catenin overexpression at invasive front in rectal carcinoma is associated with lymph node metastasis and prognosis.

Methods

Immunohistochemistry was adopted to detect the expression of β-catenin in rectal carcinoma and lymph node metastatic lesions. Spearman’s rank correlation analysis and Tukey’s test were used to evaluate the association between nuclear β-catenin expression at invasive front in rectal carcinoma and lymph node metastasis. Kaplan–Meier method and multivariate Cox regression model were used to evaluate the prognostic value of nuclear β-catenin overexpression at invasive front in rectal carcinoma for disease-free survival (DFS) and overall survival (OS).

Results

Overexpression of nuclear β-catenin at the invasive front in rectal carcinoma in stage III-N2 was significantly higher than that in stage III-N1 (73.4 vs. 40.4 %, P < 0.001). Nuclear β-catenin expression at the invasive front in rectal carcinoma was associated with the expression of nuclear β-catenin in corresponding lymph node metastatic lesions (r = 0.297, P < 0.001). Overexpression of nuclear β-catenin at the invasive front in rectal carcinoma was correlated with the number of metastatic lymph nodes (P < 0.001). Patients with nuclear β-catenin overexpression at the invasive front in rectal carcinoma had poor DFS (P = 0.002) and OS (P = 0.003). Moreover, overexpression of nuclear β-catenin at the invasive front was an independent prognosticator for unfavorable DFS and OS (P = 0.002 and 0.001).

Conclusions

Our findings suggest that overexpression of nuclear β-catenin at the invasive front in rectal carcinoma may be a useful marker to evaluate lymph node metastasis, as well as a promising predictor of poor prognosis.
Literature
1.
2.
go back to reference Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11:50–4.PubMedCrossRef Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11:50–4.PubMedCrossRef
3.
go back to reference Punt CJ, Tol J. More is less-combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol. 2009;6:731–3.PubMedCrossRef Punt CJ, Tol J. More is less-combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol. 2009;6:731–3.PubMedCrossRef
4.
go back to reference Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27:83–90.PubMedCrossRef Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27:83–90.PubMedCrossRef
5.
go back to reference Obeidat NA, Pradel FG, Zuckerman IH, DeLisle S, Mullins CD. Outcomes of irinotecan-based chemotherapy regimens in elderly. Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother. 2009;7:343–54.PubMedCrossRef Obeidat NA, Pradel FG, Zuckerman IH, DeLisle S, Mullins CD. Outcomes of irinotecan-based chemotherapy regimens in elderly. Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother. 2009;7:343–54.PubMedCrossRef
6.
go back to reference Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol. 2009;217:307–17.PubMedCrossRef Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol. 2009;217:307–17.PubMedCrossRef
7.
go back to reference Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744–9.PubMedCrossRef Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744–9.PubMedCrossRef
8.
go back to reference Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150–8.PubMedCrossRef Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150–8.PubMedCrossRef
9.
go back to reference El-Gendi S, Al-Gendi A. Assessment of tumor budding in colorectal carcinoma: correlation with β-catenin nuclear expression. J Egypt Natl Canc Inst. 2011;23:1–9.PubMedCrossRef El-Gendi S, Al-Gendi A. Assessment of tumor budding in colorectal carcinoma: correlation with β-catenin nuclear expression. J Egypt Natl Canc Inst. 2011;23:1–9.PubMedCrossRef
10.
go back to reference Wang L, Cheng H, Liu Y, Wang L, Yu W, Zhang G, et al. Prognostic value of nuclear β-catenin overexpression at invasive front in colorectal cancer for synchronous liver metastasis. Ann Surg Oncol. 2011;18:1553–9.PubMedCrossRef Wang L, Cheng H, Liu Y, Wang L, Yu W, Zhang G, et al. Prognostic value of nuclear β-catenin overexpression at invasive front in colorectal cancer for synchronous liver metastasis. Ann Surg Oncol. 2011;18:1553–9.PubMedCrossRef
11.
go back to reference Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer. 2009;115:2063–70.PubMedCrossRef Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer. 2009;115:2063–70.PubMedCrossRef
12.
go back to reference Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.PubMedCentralPubMedCrossRef Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.PubMedCentralPubMedCrossRef
13.
go back to reference Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J Clin Oncol. 2010;28:1240–6.PubMedCentralPubMedCrossRef Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J Clin Oncol. 2010;28:1240–6.PubMedCentralPubMedCrossRef
14.
go back to reference Ferrari A, Miceli R, Meazza C, Casanova M, Favini F, Morosi C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol. 2010;28:1322–8.PubMedCrossRef Ferrari A, Miceli R, Meazza C, Casanova M, Favini F, Morosi C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol. 2010;28:1322–8.PubMedCrossRef
15.
go back to reference Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 2010;28:984–90.PubMedCrossRef Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 2010;28:984–90.PubMedCrossRef
16.
go back to reference Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9.PubMedCrossRef Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9.PubMedCrossRef
17.
go back to reference Stephen EB, David BR, Carolyn CC, April FG, Frederick GL, Andy T. Colon and rectum. AJCC Cancer Staging Manual. New York: Springer; 2010. p. 143–64. Stephen EB, David BR, Carolyn CC, April FG, Frederick GL, Andy T. Colon and rectum. AJCC Cancer Staging Manual. New York: Springer; 2010. p. 143–64.
18.
go back to reference Umemura K, Takagi S, Shimada T, Masuda T, Shiga H, Takahashi S, et al. Prognostic and diagnostic significance of tumor budding associated with β-catenin expression in submucosal invasive colorectal carcinoma. Tohoku J Exp Med. 2012;229:53–9.CrossRef Umemura K, Takagi S, Shimada T, Masuda T, Shiga H, Takahashi S, et al. Prognostic and diagnostic significance of tumor budding associated with β-catenin expression in submucosal invasive colorectal carcinoma. Tohoku J Exp Med. 2012;229:53–9.CrossRef
19.
go back to reference Jang KY, Kim YN, Bae JS, Chung MJ, Moon WS, Kang MJ, et al. Expression of cyclin D1 is associated with β-catenin expression and correlates with good prognosis in colorectal adenocarcinoma. Transl Oncol. 2012;5:370–8.PubMedCentralPubMedCrossRef Jang KY, Kim YN, Bae JS, Chung MJ, Moon WS, Kang MJ, et al. Expression of cyclin D1 is associated with β-catenin expression and correlates with good prognosis in colorectal adenocarcinoma. Transl Oncol. 2012;5:370–8.PubMedCentralPubMedCrossRef
20.
go back to reference Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, et al. Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17:955–63.PubMedCentralPubMedCrossRef Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, et al. Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17:955–63.PubMedCentralPubMedCrossRef
Metadata
Title
Overexpression of nuclear β-catenin at invasive front in rectal carcinoma is associated with lymph node metastasis and poor prognosis
Authors
L. Wang
X. Zhang
Z. Li
J. Chai
G. Zhang
Z. Yu
Y. Cheng
S. Hu
Publication date
01-05-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1108-z

Other articles of this Issue 5/2014

Clinical and Translational Oncology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine